Legislation to remove CMS restrictions on anemia drugs

10/2/2007 | Hill, The

A Democrat and a Republican have introduced legislation in Congress that would overturn a July CMS decision to restrict reimbursements for erythropoiesis-stimulating drugs that treat anemia in cancer patients. The legislation says the CMS policy puts patients at risk by restricting access to the drugs, including Amgen's Epogen and Aranesp and Johnson & Johnson's Procrit.

View Full Article in:

Hill, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX